The European Cannabis Report TM July 2018 3rd Edition TM The European Cannabis Report | Table of Contents 2 3rd Edition Table of Contents Introduction 6 Lead Sponsor Foreword 7 Executive Summary 9 An Introduction to Medical Cannabis 10 Market Size 12 Market Overview Methodology Medical Recreational Industrial Legislation 15 Overview Medical Recreational Industrial The Process of Legal Reform Regulation 20 Overview The United Nations Medical Cannabis Programs Cannabis Agencies Healthcare 22 Potential Qualifying Conditions Healthcare Analysis Commercial Opportunities 23 Corporate Social Responsibility 25 Key Countries 28 Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 3 3rd Edition Table of Contents Germany 29 Czech Republic 54 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel Spain 35 France 59 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel The Netherlands 40 Ireland 64 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Israel 45 Portugal 68 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Italy 49 The United Kingdom 72 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 4 3rd Edition Table of Contents Poland 76 Luxembourg 97 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. European Panel 6. European Panel Greece 81 Denmark 101 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. European Panel 5. Consumption Switzerland 85 Sweden 105 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. European Panel 5. Consumption Austria 89 Norway 109 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption Belgium 93 Finland 113 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 5 3rd Edition Table of Contents Estonia 117 Macedonia 134 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption Slovenia 121 Romania 137 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption Croatia 125 Turkey 141 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 6. European Panel Serbia 130 Malta 145 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities Global Industry Insights 148 European Industry Insights 149 Contributors 151 About Prohibition Partners 152 Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Introduction 6 3rd Edition Introduction: The 3rd Edition of the European Cannabis Report™ In just six months, the European cannabis industry has I would like to thank the support of our sponsors, grown more than in the previous five years. Over six new members of our European Country Panel and the countries have announced legalisation, patient numbers dedicated team at Prohibition Partners who are have grown by 40% month on month and over €150m has committed to providing the most comprehensive data been invested in the European industry alone. and insights on the European cannabis industry. The 3rd Edition of The European Cannabis Report™ is I hope you enjoy the report. the most extensive review of the European cannabis industry to date. The report looks at legislation, Stephen Murphy regulation, market size and market opportunities in over Co-Founder & Managing Director 28 European countries, all of which is intricately detailed Prohibition Partners over 150 pages. Lead Sponsor Foreword The European cannabis market presents the world’s the MedReleaf footprint across additional European largest opportunity to expand in the cannabis space. The countries. tides are shifting as countries have increasingly moved toward legalising medical cannabis, bringing greater As the demand for premium medical cannabis products visibility and credibility to this growth industry. And continues to rise, MedReleaf is well positioned to lend although the health and financial benefits of medical our expertise in research and development in this highly cannabis have been well publicised, what has yet to specialised field. Our stringent quality controls are be determined is how control and classification of this aimed at ensuring that pharmaceutical grade standards category will unfold. are not just met, but exceeded. In our constant pursuit of introducing new products to global markets, MedReleaf As Canada’s first and only ISO 9001 and ICH-GMP was the first Canadian licensed producer to offer a certified cannabis producer, MedReleaf is ideally topical cream to be used with CBD cannabis oils, as well suited to expand into this burgeoning market. Outside as other important innovations like colour-coded softgel of Canada, federally legal markets for cannabis are capsules with a focus on patient-safety. Boasting an primarily focused on medical applications, which extensive plant breeding program with geneticists and aligns well with MedReleaf’s core strengths in research master growers providing expertly cultivated cannabis and development, innovation, quality control and varieties in a broad and unique product offering, we pharmaceutical grade standards. A mission to advance have consistently differentiated ourselves as industry the science of cannabis by delivering a consistently leaders and innovators. high product and high-quality experience, serves us well as we expand our global network of partners and MedReleaf is committed to executing on our European regulators. market-entry strategy in a measured and thoughtful manner and look forward to fostering positive With an announced German distribution agreement relationships with partners and regulators across the and a number of other EU distribution agreements European Union as the cannabis industry continues to and activities on the horizon, we look forward to evolve and mature. continuing to establish new partnerships and broaden Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice.